Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139124 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
A Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT02139124: Completed Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
NCT02139124 is a Phase 3 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 375 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02139124, a Phase 3 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
Primary Outcome
Participants were monitored for 4 weeks on treatment (final 2 weeks on stable dose). Clinicians rated subject behavior on the ADHD-5-Rating Scale each week. Primary outcome was based on the final week of treatment. The ADHD-5-RS is an 18-item questionnaire that measures the frequency of ADHD symptoms based on DSM-5 criteria. For each item, clinicians rate how often the behavior is displayed on a scale of 0 (Never or Rarely) to 3 (Very Often). Scores can range from 0 to 54, with lower scores indi
Interventions
- DRUG Placebo
- DRUG PRC-063 25 mg
- DRUG PRC-063 45 mg
- DRUG PRC-063 70 mg
- DRUG PRC-063 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
What the finished NCT02139124 record still lists
NCT02139124 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02139124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02139124 about?
NCT02139124 is a clinical study titled "The Efficacy and Safety of PRC-063 in Adult ADHD Patients". The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
What is the current status of trial NCT02139124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2014-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02139124?
The interventions under investigation include: Placebo (DRUG), PRC-063 25 mg (DRUG), PRC-063 45 mg (DRUG), PRC-063 70 mg (DRUG), PRC-063 100 mg (DRUG).
Who is sponsoring clinical trial NCT02139124?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02139124's enrollment target sits among peer trials
375 988th of 2000 higher than 1,010 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia